Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of a 0.05% cyclosporine a topical nanoemulsion in dry eyes with obstructive meibomian gland dysfunction

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the efficacy of topical cyclosporin A (CsA) in obstructive meibomian gland dysfunction (MGD).

Study design

Prospective, randomized, single-blinded, controlled clinical study.

Methods

Fifty-one patients with obstructive MGD were randomly assigned to one of two groups. The CsA group received 0.05% CsA topical nanoemulsion (Cyporin N®; Taejoon Pharm) twice daily, 0.15% hyaluronic acid eye drops four times daily, and 10 min of warm compress placement on the eyelids twice daily. In the control group, 0.15% hyaluronic acid eye drops were administered six times daily and warm compress was conducted twice daily for 10 min. The ocular surface disease index (OSDI), Schirmer 1 test, tear film break-up time (TBUT), corneal and conjunctival surface staining using fluorescein, eyelid debris and eyelid redness/swelling, upper and lower meibomian gland (MG) secretion scores, and upper and lower MG loss were assessed at the three-month visits.

Results

There were no significant differences in observed parameters between the two groups at baseline. At the three-month evaluation, the CsA group showed significantly better improvements in the TBUT, eyelid debris, eyelid redness/swelling, and lower MG secretion score (P < 0.001, P < 0.001, P < 0.001, and P < 0.001, respectively). There was no improvement in upper or lower MG loss in either group.

Conclusion

Treatment with 0.05% CsA nanoemulsion in combination with warm compress twice daily alleviated signs of dry eyes with obstructive MGD. However, although MG secretion was improved, glandular loss could not be restored with three months of CsA nanoemulsion treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Foulks GN, Nichols KK, Bron AJ, Holland EJ, McDonald MB, Nelson JD. Improving awareness, identification, and management of meibomian gland dysfunction. Ophthalmology. 2012;119:S1-12.

    Article  Google Scholar 

  2. Suzuki T. Inflamed obstructive meibomian gland dysfunction causes ocular surface inflammation. Invest Ophthalmol Vis Sci 2018;59:Des94-des101.

  3. Nelson JD, Shimazaki J, Benitez-del-Castillo JM, Craig JP, McCulley JP, Den S, et al. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci. 2011;52:1930–7.

    Article  Google Scholar 

  4. Borchman D. The optimum temperature for the heat therapy for meibomian gland dysfunction. Ocul Surf. 2019;17:360–4.

    Article  Google Scholar 

  5. Wu X, Chen X, Ma Y, Lin X, Yu X, He S, et al. Analysis of tear inflammatory molecules and clinical correlations in evaporative dry eye disease caused by meibomian gland dysfunction. Int Ophthalmol. 2020;40:3049–58.

    Article  Google Scholar 

  6. Qiao J, Yan X. Emerging treatment options for meibomian gland dysfunction. Clin Ophthalmol. 2013;7:1797–803.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Thode AR, Latkany RA. Current and emerging therapeutic strategies for the treatment of meibomian gland dysfunction (MGD). Drugs. 2015;75:1177–85.

    Article  CAS  Google Scholar 

  8. Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F, Gurny R. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm. 2003;56:307–18.

    Article  CAS  Google Scholar 

  9. Bang SP, Yeon CY, Adhikari N, Neupane S, Kim H, Lee DC, et al. Cyclosporine A eyedrops with self-nanoemulsifying drug delivery systems have improved physicochemical properties and efficacy against dry eye disease in a murine dry eye model. PLoS One 2019;14:e0224805.

  10. Lallemand F, Schmitt M, Bourges JL, Gurny R, Benita S, Garrigue JS. Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts. Eur J Pharm Biopharm. 2017;117:14–28.

    Article  CAS  Google Scholar 

  11. Yang S, Byun Y-S, Rho CR, Kim SY, Cho YK, Kim EC, et al. Comparisons for evaluation of efficacy and safety of cyclosporin a 0.05% ophthalmic emulsion treatment groups. Journal of the Korean Ophthalmological Society 2016;57:1849–56.

  12. Kang MJ, Kim YH, Chou M, Hwang J, Cheon EJ, Lee HJ, et al. Evaluation of the efficacy and safety of a novel 0.05% cyclosporin A topical nanoemulsion in primary Sjögren's syndrome dry eye. Ocul Immunol Inflamm 2020;28:370–8.

  13. Eom Y, Na KS, Cho KJ, Hwang HS, Kim SW, Chung TY, et al. Distribution and characteristics of meibomian gland dysfunction subtypes: a multicenter study in South Korea. Korean J Ophthalmol. 2019;33:205–13.

    Article  CAS  Google Scholar 

  14. Viso E, Rodríguez-Ares MT, Abelenda D, Oubiña B, Gude F. Prevalence of asymptomatic and symptomatic meibomian gland dysfunction in the general population of Spain. Invest Ophthalmol Vis Sci. 2012;53:2601–6.

    Article  Google Scholar 

  15. Eom Y, Na KS, Hwang HS, Cho KJ, Chung TY, Jun RM, et al. Clinical efficacy of eyelid hygiene in blepharitis and meibomian gland dysfunction after cataract surgery: a randomized controlled pilot trial. Sci Rep. 2020;10:11796.

    Article  CAS  Google Scholar 

  16. Tsubota K, Yokoi N, Shimazaki J, Watanabe H, Dogru M, Yamada M, et al. New perspectives on dry eye definition and diagnosis: a consensus report by the Asia Dry Eye Society. Ocul Surf. 2017;15:65–76.

    Article  Google Scholar 

  17. Eom Y, Hyon JY, Lee HK, Song JS, Kim HM. A multicenter cross-sectional survey of dry eye clinical characteristics and practice patterns in Korea: the DECS-K study. Jpn J Ophthalmol. 2021;65:261–70.

    Article  Google Scholar 

  18. Eom Y, Kim HM. Clinical effectiveness of diquafosol ophthalmic solution 3% in Korean patients with dry eye disease: a multicenter prospective observational study. Int J Ophthalmol. 2021;14:1518–26.

    Article  Google Scholar 

  19. Lacroix Z, Léger S, Bitton E. Ex vivo heat retention of different eyelid warming masks. Cont Lens Anterior Eye. 2015;38:152–6.

    Article  Google Scholar 

  20. Tichenor AA, Cox SM, Ziemanski JF, Ngo W, Karpecki PM, Nichols KK, et al. Effect of the Bruder moist heat eye compress on contact lens discomfort in contact lens wearers: An open-label randomized clinical trial. Cont Lens Anterior Eye. 2019;42:625–32.

    Article  Google Scholar 

  21. Luchs J. Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. Adv Ther. 2008;25:858–70.

    Article  CAS  Google Scholar 

  22. Fadlallah A, Rami HE, Fahd D, Dunia I, Bejjani R, Chlela E, et al. Azithromycin 1.5% ophthalmic solution: efficacy and treatment modalities in chronic blepharitis. Arq Bras Oftalmol 2012;75:178–82.

  23. Efron, Nathan (2000) Efron grading scales for contact lens complications (Millennium Edition), Butterworth-Heinemann. Available at: https://eprints.qut.edu.au/11857/1/11857a.pdf. Accessed 22 Dec 2020.

  24. Tomlinson A, Bron AJ, Korb DR, Amano S, Paugh JR, Pearce EI, et al. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci. 2011;52:2006–49.

    Article  Google Scholar 

  25. Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocul Surf. 2003;1:107–26.

    Article  Google Scholar 

  26. Perry HD, Doshi-Carnevale S, Donnenfeld ED, Solomon R, Biser SA, Bloom AH. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea 2006;25:171–5.

  27. Prabhasawat P, Tesavibul N, Mahawong W. A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction. Cornea 2012;31:1386–93.

  28. Kang HG, Zhang D, Degauque N, Mariat C, Alexopoulos S, Zheng XX. Effects of cyclosporine on transplant tolerance: the role of IL-2. Am J Transplant. 2007;7:1907–16.

    Article  CAS  Google Scholar 

  29. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991;66:807–15.

    Article  CAS  Google Scholar 

  30. Perry HD, Solomon R, Donnenfeld ED, Perry AR, Wittpenn JR, Greenman HE, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol. 2008;126:1046–50.

    Article  Google Scholar 

  31. Knop E, Knop N, Millar T, Obata H, Sullivan DA. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci. 2011;52:1938–78.

    Article  Google Scholar 

  32. Eom Y, Han JY, Kang B, Hwang HS, Lee HK, Kim HM, et al. Meibomian glands and ocular surface changes after closure of meibomian gland orifices in rabbits. Cornea. 2018;37:218–26.

    Article  Google Scholar 

  33. Reyes N, Saban DRJIO, Science V. Pathogenesis of meibomian gland dysfunction (MGD) requires the T cell-neutrophil axis, in the allergy setting. 2016;57:1431.

  34. Kim HY, Lee JE, Oh HN, Song JW, Han SY, Lee JS. Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction. Int J Ophthalmol 2018;11:593–600.

  35. Knop E. Knop N [Meibomian glands : part IV. Functional interactions in the pathogenesis of meibomian gland dysfunction (MGD)]. Ophthalmologe. 2009;106:980–7.

    Article  CAS  Google Scholar 

  36. Fukuoka S, Arita R. Increase in tear film lipid layer thickness after instillation of 3% diquafosol ophthalmic solution in healthy human eyes. Ocul Surf. 2017;15:730–5.

    Article  Google Scholar 

  37. Arita R, Suehiro J, Haraguchi T, Maeda S, Maeda K, Tokoro H, et al. Topical diquafosol for patients with obstructive meibomian gland dysfunction. Br J Ophthalmol. 2013;97:725–9.

    Article  Google Scholar 

  38. Maskin SL, Testa WR. Growth of meibomian gland tissue after intraductal meibomian gland probing in patients with obstructive meibomian gland dysfunction. Br J Ophthalmol. 2018;102:59–68.

    Article  Google Scholar 

  39. Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15:802–12.

    Article  Google Scholar 

  40. Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009;54:321–38.

    Article  Google Scholar 

  41. Bilkhu PS, Naroo SA, Wolffsohn JS. Randomised masked clinical trial of the MGDRx EyeBag for the treatment of meibomian gland dysfunction-related evaporative dry eye. Br J Ophthalmol. 2014;98:1707–11.

    Article  Google Scholar 

  42. Ngo W, Srinivasan S, Jones L. An eyelid warming device for the management of meibomian gland dysfunction. J Optom. 2019;12:120–30.

    Article  Google Scholar 

  43. Villani E, Garoli E, Canton V, Pichi F, Nucci P, Ratiglia R. Evaluation of a novel eyelid-warming device in meibomian gland dysfunction unresponsive to traditional warm compress treatment: an in vivo confocal study. Int Ophthalmol. 2015;35:319–23.

    Article  Google Scholar 

  44. Kim HS, Kim TI, Kim JH, Yoon KC, Hyon JY, Shin KU, et al. Evaluation of clinical efficacy and safety of a novel cyclosporin A nanoemulsion in the treatment of dry eye syndrome. J Ocul Pharmacol Ther. 2017;33:530–8.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by a TRC Research Grant of the Korea University Medicine and Korea Institute of Science and Technology, by Korea University Ansan Hospital grant, by Korea University Grants (K1625491, K1722121, K1811051, K1913161, and K2010921), by the Korea Medical Device Development Fund grant funded by the Korea government (the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health & Welfare, the Ministry of Food and Drug Safety) (Project Number: 9991007583, KMDF_PR_20200901_0296), by Korea Environment Industry & Technology Institute(KEITI) through Technology Development Project for Safety Management of Household Chemical Products, funded by Korea Ministry of Environment(MOE) (2020002960007, NTIS-1485017544), by the Technology development Program(S3127902) funded by the Ministry of SMEs and Startups(MSS, Korea), by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MSIT) (No. NRF-2021R1F1A1062017), and by Taejoon Pharm, Korea (TJP-1902-501).

Author information

Authors and Affiliations

  1. Miso Eye Clinic, Seoul, Republic of Korea

    Jay Won Rhim

  2. Department of Ophthalmology, Korea University Ansan Hospital, 123, Jeokgeum-ro, Danwon-gu, Ansan-si, Gyeonggi-do, 15355, Republic of Korea

    Youngsub Eom, Eun Gyu Yoon, Seo Yeon Park & Young Choi

  3. Department of Ophthalmology, Korea University College of Medicine, Seoul, Republic of Korea

    Youngsub Eom, Eun Gyu Yoon, Young Choi, Jong Suk Song & Hyo Myung Kim

Authors
  1. Jay Won Rhim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Youngsub Eom
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eun Gyu Yoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seo Yeon Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Young Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jong Suk Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hyo Myung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Youngsub Eom.

Ethics declarations

Conflicts of interest

J. W. Rhim, None; Y. Eom, None; E. G. Yoon, None; S. Y. Park, None; Y. Choi, None; J. S. Song, None; H. M. Kim, None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Corresponding Author: Youngsub Eom

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rhim, J.W., Eom, Y., Yoon, E.G. et al. Efficacy of a 0.05% cyclosporine a topical nanoemulsion in dry eyes with obstructive meibomian gland dysfunction. Jpn J Ophthalmol 66, 254–263 (2022). https://doi.org/10.1007/s10384-022-00906-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-022-00906-3

Keywords

Search

Navigation